Director / Editor: Victor Teboul, Ph.D.
Looking inside ourselves and out at the world
Independent and neutral with regard to all political and religious orientations,® aims to promote awareness of the major democratic principles on which tolerance is based.

The FDA’s weak drug manufacturing oversight is a potentially deadly problem

By Adrian V. Hernandez, Associate Professor of Comparative Effectiveness and Outcomes Research, University of Connecticut
C. Michael White, Distinguished Professor and Head of the Department of Pharmacy Practice, University of Connecticut
Share this article
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

Read complete article

© The Conversation -

Follow us on ...
Facebook Twitter